Drug Discovery and Development Forum 2019

New Trends in Small Molecule Drug Discovery: Artificial Intelligence, Cancer-Cell Vulnerabilities and Immunology

The Drug Discovery and Development Forum 2019 will highlight New Trends in Small Molecule Drug Discovery: Artificial Intelligence, Cancer-Cell Vulnerabilities and Immunology.

When: September 30th to October 2nd 2019

Where: Centre for Translational Biology
McGill University Health Centre
1001 Decarie Boulevard, Bloc E
Montreal, Quebec H4A 3J1

Challenges in Drug Discovery and Clinical Development Forum MUHC McGill University CIHR

Accommodations at special conference rates are available: $60-$220 CAD/night

IN ORDER TO BENEFIT FROM THE SPECIAL RATES PLEASE WRITE TO US AT:

DDTP Office
1001 Décarie Boulevard Room ES15565
Montreal Quebec
H4A 3J1
Email: trainingindrugdev.med@mcgill.ca
Tel: (514) 934-1934 Ext: 76435

For more information, please contact us at:
Tel: (514)934-1934 ext. 76435
Trainingindrugdev.med@mcgill.ca

Click on the frame to view DDTP activities

Meet our speakers

Dr. Mildred Duncan-Avecedo

Professor
Principal Investigator - Merit Review Program, James A. Haley Veterans’ Hospital Department of Chemistry
University of South Florida USA

Presentation Title

PKC-ι and PKC-ζ are heavily responsible of upregulating epithelial-mesenchymal transition (EMT) & activating Vimentin to facilitate cellular motility in prostate cancer cell lines

Ornella Franzese, PhD

Assistant Professor
Department of Systems Medicine, School of Medicine
University of Rome Tor Vergata, Rome, Italy

Presentation Title

Drug-induced Xenogenization: new frontiers in cancer chemoimmunotherapy

Dr. Lana E. Janes

Venture Partner
adMare BioInnovations, CDRD Centre for Drug Research & Development
Vancouver, BC

Presentation Title

Design, synthesis and development of the next generation of radiopharmaceuticals as precision oncology therapeutics

Dr. Shahar Keinan

Chief Scientific Officer
Cloud Pharmaceuticals, Inc.
North Carolina, USA

Presentation Title

Machine learning (ML) and artificial intelligence (AI) in the design of new drug lead compounds

Dr. Anne Marinier

Director of Medicinal Chemistry
Institut de recherche en immunologie et en cancérologie (IRIC)
Université de Montréal, QC

Presentation Title

Chemo-genomic screening in AML: a new approach to identify therapeutic strategies in cancer

Dr. Anne-Marie Mes-Masson

Professor & Associate Scientific Director
Centre de recherche CHUM et Institut du cancer de Montréal
Montréal, QC

Presentation Title

Targeting genome instability as an essential vulnerability in ovarian cancer

Dr. Alain Nepveu

Professor
Goodman Cancer Research Center and Departments of Oncology, Biochemistry and Medicine
McGill University, Montreal, QC

Presentation Title

Validation of a Therapeutic Target and Development of a High-Throughput Screen to Identify CUT Domain Inhibitors

Dr. Josh Pottel

President and CEO
Molecular Forecaster Inc. Montreal, QC
DDTP Alumnus

Presentation Titile

Accelerating Drug Discovery in Academia and Industry with Just a Few Clicks- Accessible Computational Workflows to Design Custom Experiments

Lijun Sun, PhD

Associate Professor, Harvard Medical School
Director, Center for Drug Discovery & Translational Research
Beth Israel Deaconess Medical Center, USA

Presentation Titile

Characterization of 3-Acylindoles as Potent AHR Agonists: Molecular Dynamics Simulation, Structure-Activity Relationship, and Therapeutic Application in Colitis

Dr. Jian Hui Wu

Associate Professor, Lady Davis Institute for Medical Research
Sir Mortimer B.D.-Jewish General Hospital
Departments of Oncology and Medicine
McGill University, Montreal, QC

Presentation Titile

Discovery of Novel Compounds Targeting the N-terminal Domain of the Androgen Receptor for Castration-Resistant Prostate Cancer